Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 226 to 250 of 797

TitleReference numberPublishedLast updated
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancerTA801
Cemiplimab for treating advanced cutaneous squamous cell carcinomaTA802
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiationTA798
Venetoclax for treating chronic lymphocytic leukaemiaTA796
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal)TA797
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal)TA793
Diroximel fumarate for treating relapsing–remitting multiple sclerosisTA794
Ibrutinib for treating Waldenstrom's macroglobulinaemiaTA795
Filgotinib for treating moderately to severely active ulcerative colitisTA792
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal)TA790
Romosozumab for treating severe osteoporosisTA791
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterationsTA789
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapyTA788
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapiesTA786
Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitableTA787
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancerTA784
Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal)TA785
Daratumumab monotherapy for treating relapsed and refractory multiple myelomaTA783
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancerTA781
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal)TA782
Nivolumab with ipilimumab for untreated advanced renal cell carcinomaTA780
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA779
Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal)TA774
Empagliflozin for treating chronic heart failure with reduced ejection fractionTA773
Dapagliflozin for treating chronic kidney diseaseTA775

Results per page

  1. 10
  2. 25
  3. 50
  4. All